Greenleaf Trust Purchases 405 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Greenleaf Trust grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.0% during the fourth quarter, HoldingsChannel reports. The firm owned 2,938 shares of the biopharmaceutical company’s stock after buying an additional 405 shares during the period. Greenleaf Trust’s holdings in Alnylam Pharmaceuticals were worth $562,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quent Capital LLC boosted its stake in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $38,000. Acadian Asset Management LLC boosted its stake in Alnylam Pharmaceuticals by 52.4% during the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 311 shares in the last quarter. Avitas Wealth Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $204,000. Finally, EP Wealth Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 71 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $145.79 on Tuesday. The firm has a 50-day moving average of $151.09 and a 200-day moving average of $166.50. The company has a market cap of $18.36 billion, a P/E ratio of -40.95 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $143.50 and a one year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. During the same quarter last year, the business posted ($1.68) EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of several research analyst reports. Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. BMO Capital Markets reissued an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 13th. JPMorgan Chase & Co. upped their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. Nine analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.